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One Sentence Summary: 
At 96 weeks after unilateral intravitreal injection of rAAV2/2-ND4, vision improved in both eyes 





 Submitted Manuscript:  Confidential               
 
Abstract: 
REVERSE is a randomized, double-masked, sham-controlled, multicenter, phase III clinical trial 
that evaluated the efficacy of a single intravitreal injection of rAAV2/2-ND4 in subjects with 
visual loss from Leber hereditary optic neuropathy (LHON). A total of 37 subjects carrying the 
m.11778G>A (MT-ND4) mutation and with duration of vision loss between 6 to 12 months were 
treated. Each subject’s right eye was randomly assigned in a 1:1 ratio to treatment with 
rAAV2/2-ND4 (GS010) or sham injection. The left eye received the treatment not allocated to 
the right eye. Unexpectedly, sustained visual improvement was observed in both eyes over the 
96-week follow-up period. At Week 96, rAAV2/2-ND4-treated eyes showed a mean 
improvement in best-corrected visual acuity (BCVA) of -0.308 LogMAR (+15 ETDRS letters). 
A mean improvement of -0.259 (0.068) LogMAR (+13 ETDRS letters) was observed in the 
sham-treated eyes. Consequently, the primary endpoint, defined as the difference in the change 
in BCVA from baseline to Week 48 between the two treatment groups, was not met (p = 0.894, 
ANCOVA). At Week 96, 25 subjects (68%) had a clinically relevant recovery in BCVA from 
baseline in at least one eye and 29 subjects (78%) had an improvement in vision in both eyes.  A 
non-human primate study was conducted to investigate this bilateral improvement. Evidence of 
transfer of viral vector DNA from the injected eye to the anterior segment, retina and optic nerve 
of the contralateral non-injected eye supports a plausible mechanistic explanation for the 
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Introduction 
Leber hereditary optic neuropathy (LHON) is a maternally-inherited blinding bilateral optic 
neuropathy (1). It is the most common primary mitochondrial DNA (mtDNA) disorder, affecting 
approximately 1 in 30,000 to 1 in 50,000 people, particularly young adult males (2). The 
pathophysiology of LHON is characterized by selective loss of retinal ganglion cells (RGCs) and 
their axons, which leads to rapidly progressive bilateral vision loss. The visual prognosis is poor 
and most patients progress to vision worse than 20/200 within the first year following disease 
onset (3). Three mtDNA point mutations account for approximately 90% of all LHON cases, 
namely m.3460G>A (MT-ND1), m.11778G>A (MT-ND4), and m.14484T>C (MT-ND6), with 
m.11778G>A being the most common mutation worldwide (1,3,4). These mutations affect 
complex I subunits of the mitochondrial respiratory chain, impairing mitochondrial function and 
increasing the production of reactive oxygen species. RGCs appear to be selectively vulnerable 
to mitochondrial dysfunction resulting in apoptotic cell death, optic nerve degeneration and the 
development of optic atrophy (3). 
The current treatment for LHON remains limited (5). Idebenone (Raxone, Santhera) was 
granted market authorization in the European Union for treatment of LHON under exceptional 
circumstances (6). LHON is especially amenable to gene therapy as it has a well-defined onset 
with an expected natural history. Furthermore, the biological targets, the RGCs, are easily 
accessible for gene delivery through standard intravitreal injection (7). 
Over the past decade, substantial progress has been made in the application of gene 
therapy to monogenic blinding diseases, with the first treatment approved by both American and 
European regulatory agencies for an inherited retinal degenerative disorder, namely Leber 
congenital amaurosis caused by recessive RPE65 mutations (8). Gene therapy in mitochondrial 
disorders is challenging as the wild-type protein needs to reach the mitochondrial matrix 
compartment by crossing the mitochondrial outer and inner membranes. The allotopic expression 
strategy involves the nuclear expression of the wild-type recoded replacement mitochondrial 
gene, which having been engineered to carry a mitochondrial targeting sequence (MTS), results 
in mRNA translation and co-translocation of the protein into mitochondria (9). This strategy has 
been successfully applied in cell models and safely translated in induced rodent LHON models 
with preservation of RGCs and visual function (10-14). 
rAAV2/2-ND4 (GS010) is a recombinant replication-defective adeno-associated virus, 
serotype 2, which contains a modified cDNA encoding the human wild-type mitochondrial ND4 
protein and a specific MTS for translocation of the protein into the mitochondrial matrix. 
rAAV2/2-ND4 has been shown to efficiently rescue an induced defect in mitochondrial 
respiratory chain complex I in a rat model of the disease (13), and it was able to restore 
complex I activity and ATP synthesis in cultured LHON fibroblasts carrying the m.11778G>A 
mutation (14). Based on these preclinical studies, a first-in-human trial (GS-LHON-CLIN-01) 
showed that a single intravitreal administration of increasing doses of rAAV2/2-ND4 was safe 
and well-tolerated in LHON subjects (15,16). Three ongoing clinical trials are examining the 
efficacy of intravitreal injection of rAAV2/2-ND4 (GS010) in LHON subjects with the 
m.11778G>A mutation and with vision loss within one year (RESCUE NCT02652767, 
REVERSE NCT02652780 and REFLECT NCT03293524). Here, we report the 96-week results 
of the phase 3 REVERSE trial in 37 LHON subjects carrying the m.11778G>A mutation and 
with duration of vision loss between 6 and 12 months upon inclusion. 
REVERSE was designed with unilateral intravitreal injection of rAAV2/2-ND4 and 
sham-treated fellow eye, under the assumption that the therapeutic effects of treated versus 
untreated eyes would be compared. The unexpected observation of a bilateral improvement of 
visual function prompted us to further investigate the possible transfer of rAAV2/2-ND4 viral 
vector to the contralateral sham-treated eye by conducting a non-human primate (NHP) study 
equivalent to the human REVERSE study. We confirmed the presence of viral vector DNA in 
the contralateral visual pathway, providing a plausible explanation for the clinical results 
observed in REVERSE. 
Results 
Demographics and Baseline Characteristics of the Study Population 
Thirty-seven subjects with LHON due to the m.11778G>A mutation and duration of vision loss 
between 6 to 12 months were enrolled in the multicenter REVERSE trial between February 2016 
and February 2017. Subjects were predominantly males (78.4%) with a mean age of 34.2 years at 
enrollment (Table S1). Mean duration of vision loss for rAAV2/2-ND4-treated and sham-treated 
eyes was 8.8 months and 9.3 months, respectively. At baseline, the mean (standard deviation 
[SD]) best-corrected visual acuity (BCVA) for rAAV2/2-ND4-treated and sham-treated eyes was 
1.67 (0.50) and 1.55 (0.42) logarithm of the minimal angle of resolution (LogMAR), 
respectively, and this difference was not significant (p = 0.152 by paired t-test) (Table 1). At 
enrollment, 54% of all eyes scored 0 logarithm contrast sensitivity (LogCS) on the Pelli-Robson 
chart, meaning that no more than one out of 3 letters was read correctly at highest contrast 
(100%). The mean (SD) baseline score for contrast sensitivity for rAAV2/2-ND4-treated and 
sham-treated eyes was 0.25 (0.40) and 0.35 (0.46) LogCS, respectively, with sham-treated eyes 
reporting significantly better contrast sensitivity (p = 0.032 by paired t-test) (Table S2). Fourteen 
subjects had prior use of idebenone and they all had discontinued this medication at least 7 days 
prior to enrollment. 
Efficacy Data at Week 96 
The mean (SD) change in BCVA from baseline to Week 48 was -0.218 (0.055) and -0.211 
(0.055) LogMAR in rAAV2/2-ND4-treated and sham-treated eyes, respectively. The difference 
of the change in BCVA between these two groups at Week 48 was -0.007 LogMAR (p = 0.894, 
analysis of covariance, ANCOVA). The primary endpoint, which was defined as a clinically 
significant difference of 0.3 LogMAR between treated and sham-treated eyes, was, therefore, not 
met. At Week 96, rAAV2/2-ND4-treated eyes showed a mean (SD) improvement in BCVA of 
-0.308 (0.068) LogMAR, equivalent to a gain of 15 Early-Treatment Diabetic Retinopathy Study 
(ETDRS) letters (p < 0.0001 for change from baseline) (Table 1). An average improvement of -
0.259 (0.068) LogMAR was observed in the sham-treated eyes, equivalent to a gain of 
13 ETDRS letters (p = 0.0001 for change from baseline). The mean change from baseline in 
BCVA increased continuously and bilaterally over the 96-week period following treatment (Fig. 
1A). 
The proportion of eyes with a clinically relevant response (CRR) in the rAAV2/2-ND4-
treated eye group (62%) was significantly higher than in the sham-treated eye group (43%) 
(p = 0.0348). Twenty-five subjects (68%) showed a CRR in at least one eye at Week 96 and 23 
of these 25 subjects (92%) had a CRR in the rAAV2/2-ND4-treated eye (Table S3). Fourteen 
(38%) subjects showed a CRR in both eyes and 9 (24%) subjects in the rAAV2/2-ND4-treated 
eye only (Fig. 1B). Two subjects (5%) showed a CRR in the sham-treated eye only. In a second 
responder analysis, an eye responder at Week 96 was defined as an on-chart improvement of at 
least -0.3 LogMAR (3 ETDRS lines) or an improvement from off-chart to on-chart vision with a 
final BCVA of 1.4 LogMAR or better (equating to at least the first 3 ETDRS lines of the chart 
being read at a distance of 1 meter). Using these criteria, the eye responder rate was 35% for 
rAAV2/2-ND4-treated eyes and 27% for sham-treated eyes (Table S3). Fifteen subjects (41%) 
had this response in at least one eye. Based on a generalized estimating equation model to assess 
treatment effect, rAAV2/2-ND4-treated eyes were 3.6 times more likely to achieve a BCVA 
better than 20/200 (p = 0.0032). Based on the identical statistical model, rAAV2/2-ND4-treated 
eyes were 2.8 times more likely to achieve a BCVA better than or equal to 20/200 (p = 0.0094). 
Most subjects showed similar BCVA changes in both eyes, as indicated by the distribution of 
data points close to the bisector, and a bilateral improvement in BCVA was observed in 29 
(78%) subjects (Fig. 1B). Amongst subjects with a bilateral improvement in BCVA from 
baseline, 44% showed an earlier improvement in the rAAV2/2-ND4-treated eye than in the sham 
eye, 15% showed an earlier improvement in the sham eye, and 41% had a simultaneous 
improvement in both eyes. On average,  rAAV2/2-ND4-treated eyes improved 66 days earlier 
than the sham eyes. 
The mean improvement from the nadir (worst BCVA for each eye of each subject) for 
rAAV2/2-ND4-treated eyes and sham-treated eyes was -0.570 LogMAR (28.5 ETDRS letters) 
and -0.490 LogMAR (24.5 ETDRS letters), respectively (Table 2). In total, 78% of REVERSE 
subjects presented a CRR from the nadir in at least one eye. 
Contrast sensitivity improved in rAAV2/2-ND4-treated and sham-treated eyes with a 
mean (SD) increase from baseline to Week 96 of 0.22 (0.06) and 0.12 (0.06) LogCS, respectively 
(Fig. S1 and Table S2). The mean deviation on automated perimetry showed a mean (SD) 
improvement of 2.70 (0.90) and 2.57 (0.90) dB in rAAV2/2-ND4-treated and sham-treated eyes, 
respectively (Table S2). There were no differences in the change of spectral-domain optical 
coherence tomography (SD-OCT) parameters from baseline to Week 96 in rAAV2/2-ND4-
treated and sham-treated eyes (Table S2).  
Patient-reported outcome measures were evaluated using the National Eye Institute 
Visual Function Questionnaire-25 (NEI VFQ-25). The change in quality of life was assessed and 
compared with the baseline values before treatment. The composite score, which is an average of 
the vision-targeted subscales scores excluding the general health rating question, showed a mean 
improvement of 9.5 points. Improvements were reported for the following subscales (22): 
dependency (+18.5, +130.2%), mental health (+16.1, +108.2%), role difficulties (+15.9, 
+78.9%), near activities (+13.3, +78.1%), peripheral vision (+10.8, +41.0%), distance activities 
(+10.7, +47.4%), color vision (+6.9, +21.6%), general vision (+6.5, +32.4%), and social 
functioning (+4.7, +32.8%) (Table S4). 
Safety Data at Week 96 
Treatment with viral vector was tolerated well, without any occurrences of discontinuation over 
the 96 weeks of follow-up. One serious adverse event (a retinal tear requiring hospitalization) 
was reported in the sham-treated eye of one subject, which was deemed clinically unrelated to 
the study drug or procedure. No prophylactic oral or topical steroids were provided before or 
immediately after the intravitreal injection. In rAAV2/2-ND4-treated eyes, the most frequent 
ocular adverse event was intraocular inflammation, which was documented in 34 (92%) eyes and 
assessed as mild for 28 (76%) eyes. Anterior and intermediate uveitis was reported in 27 (73%) 
and 25 (68%) eyes, respectively, with no posterior uveitis affecting the retina and optic nerve 
reported. The anterior uveitis was graded as mild in 23 eyes and moderate in 4 eyes. There was 
no incidence of severe anterior uveitis. The intermediate uveitis was graded as mild in 21 eyes 
and moderate in 3 eyes. One eye developed severe intermediate uveitis. Intraocular inflammation 
resolved without sequelae following standard therapy in all patients. For the 34 eyes that 
developed intraocular inflammation, 29 (85%) eyes received topical steroids for a mean duration 
of 211 days. A course of oral steroids was prescribed for 9 (26%) patients based on the 
clinician’s judgement. An increase in intraocular pressure was reported in 27% of eyes and was 
mostly mild elevation, resolving with standard therapy. No subject developed chronic ocular 
hypertension or glaucoma during follow-up. Viral vector biodissemination was assessed for all 
patients at 2 weeks post-treatment. All the tested samples showed negative quantitative PCR 
(qPCR) results, demonstrating no systemic diffusion of GS010. 
Biodistribution of rAAV2/2-ND4 (GS010) DNA Following a Single Eye Intravitreal Injection in 
Cynomolgus Monkeys 
We conducted a study using non-human primates to probe a possible mechanism underlying the 
unexpected improvement in visual function in the contralateral untreated eye following unilateral 
intravitreal administration of the viral vector in the REVERSE clinical study. Viral DNA was 
detected and quantified using ND4 transgene-specific qPCR three months following unilateral 
intravitreal injection of rAAV2/2-ND4 in three animals and vehicle formulation in one control 
animal. The qPCR protocol used specifically targeted the ND4 transgene of rAAV2/2-ND4.  
Viral DNA was neither detected (below the limit of detection, [BLD]) nor quantified (below the 
limit of quantification, [BLQ]) in the 13 sentinel control samples that were concomitantly 
extracted, indicating no cross-contamination during the extraction and the qPCR analysis. All the 
tissue samples from both eyes of the control animal (Group 1) showed no detection (BLD) of 
viral DNA three months after unilateral intravitreal injection of vehicle formulation in the right 
eye (Table 3).  
Three months after unilateral intravitreal injection of rAAV2/2-ND4 in the right eye, 
rAAV2/2-ND4 DNA was detected in all the tissue and fluid samples tested for the 3 animals 
(Table 3 and Fig. 2). When quantified, the mean quantity of rAAV2/2-ND4 ranged from 
2.84x102 to 3.21x106 vg/µg of DNA in tissue samples, and 1.65x103 and 8.70x104 copy/µL in 
the aqueous and vitreous humors, respectively. rAAV2/2-ND4 DNA was detected in the 
contralateral non-injected eyes and visual pathways in the following tissues: anterior segment of 
the eye (all 3 animals; quantifiable for the 3 animals), retina (all 3 animals; quantifiable for 2 
animals, BLQ for 1 animal), optic nerve (all 3 animals; quantifiable for the 3 animals), optic tract 
(2 animals; BLQ for the 2 animals), and lateral geniculate nucleus (2 animals; BLQ for the 2 
animals). Viral DNA was detected in the optic chiasm of all 3 animals (Table 3 and Fig. 2). No 
viral DNA was detected in the contralateral visual cortex. When quantified, the mean quantity of 
rAAV2/2-ND4 in the contralateral non-injected eyes ranged from 3.39x103 to 1.00x104 vg/µg of 
DNA. No PCR inhibition was detected in any sample. 
Discussion  
REVERSE is the largest phase III clinical trial of gene therapy in LHON for which results are 
now reported. The subjects recruited were representative of the LHON population in terms of 
demographics and baseline visual characteristics (1-4). Both the rAAV2/2-ND4-treated and 
sham-treated eyes showed an improvement in BCVA when compared with baseline and nadir 
measurements. The sustained improvement observed in the contralateral sham-injected eyes was 
unexpected and resulted in the primary endpoint at Week 48 not being met. At Week 96, the 
change from baseline of -0.308 LogMAR (+15 ETDRS letters) in rAAV2/2-ND4-treated eyes 
and -0.259 LogMAR (+13 ETDRS letters) in sham-treated eyes represents a clinically 
meaningful bilateral improvement of vision. As some subjects were still in the dynamic phase of 
the disease process upon enrollment, the visual gain from the nadir was of an even larger 
magnitude, reaching 28.5 ETDRS letters for rAAV2/2-ND4-treated eyes and 24.5 ETDRS letters 
for sham-treated eyes. At the time of study design, it was assumed that the BCVA in sham-
treated eyes would act as the placebo arm, remaining stable over time or worsening if the nadir 
of vision had not been reached at baseline. As a result, REVERSE lacks a true internal control 
group, resulting in our dependence on comparisons with previously published natural history 
figures. In the RHODOS study, which was a randomized controlled trial comparing idebenone 
with placebo in LHON patients treated within 5 years of the onset of visual loss, an improvement 
from baseline of -0.139 LogMAR (+6 ETDRS letters) was noted at Week 24 in the cohort of 35 
patients with the m.11778G>A mutation treated with placebo (17). Similar natural history results 
were reported in a larger retrospective study of a LHON cohort of idebenone-treated patients 
compared with those untreated (18). In a retrospective study that included all three common 
mtDNA LHON mutations, 82% of patients had a BCVA of 20/200 or worse at the last available 
data point, which was on average 14.9 months after the onset of vision loss (range from 2.3 to 
56.7 months) (19,20). In that study, spontaneous CRR was defined as an improvement from 
baseline either from off-chart BCVA to reading at least 5 letters on the ETDRS chart at 1 meter, 
or as an on-chart improvement of at least 10 letters on the ETDRS chart. The analysis was run on 
a cohort of 86 subjects, including childhood-onset cases. For the subgroup of 61 subjects that 
carried the m.11778G>A mutation, 15% (9/61) experienced a spontaneous CRR from baseline in 
at least one eye at the last follow-up visit. In comparison, 68% of subjects (25/37) in REVERSE 
showed a similar improvement 2 years after treatment. 
In a prospective natural history study of LHON, 12 subjects with LHON due to the 
m.11778G>A mutation and with vision loss of up to 12 months had no improvement of their 
ETDRS score after 12 months of follow up, and a slight decrease in ETDRS score at 24 months 
in 9 subjects (21). Including patients with vision loss of more than 12 months, 13 out of 88 eyes 
(15%) showed a spontaneous improvement of at least 15 ETDRS letters during follow-up, 
accounting for 18% of enrolled subjects. Childhood-onset LHON carries a better prognosis for 
spontaneous clinical recovery of vision when compared with adult-onset cases (23). The 
prospective natural history study included 8 subjects who were below the age of 15 years at the 
time of onset and 3 (38%) of those subjects were reported as being responders in at least one eye 
at their last follow-up visit. Direct comparisons between the Lam et al. study and our study are 
problematic because of the relatively small numbers in the subgroups in the Lam et al. study and 
the potential confounders of inclusion of subjects with young age at onset, enrollment of some 
patients with visual loss duration of less than 6 months, and possible patient concurrent use of 
idebenone (21). However, 38% of rAAV2/2-ND4-treated eyes and 32% of sham-treated eyes in 
REVERSE showed an improvement from baseline of at least 15 ETDRS letters at week 96, 
representing 46% of the entire study cohort, suggesting a possible better responder rate than in 
any subgroups of the Lam et al. study. 
The bilateral gain in BCVA in the REVERSE study was consistent with the trend 
observed for other visual parameters, including contrast sensitivity and visual field perimetry. 
The NEI VFQ25 questionnaire has been validated as a responsive and sensitive measure of 
vision-related quality of life (22). In REVERSE, the composite NEI VFQ25 score showed a 
mean improvement of 9.5 points, which is more than the clinically relevant threshold estimated 
at between +3.9 and +4.3 points (22). LHON has a major detrimental impact on activities of 
daily living and the substantial improvement in composite score suggests a clinically meaningful 
improvement in patient-reported outcome measures (24). 
The unexpected bilateral improvement in vision observed in REVERSE is in contrast to 
the results obtained in other gene therapies targeting photoreceptors or the retinal pigment 
epithelium with a surgical subretinal injection of the viral vector (7,25). However, an 
improvement in visual function in the untreated eye following unilateral intravitreal 
administration of the viral vector has been demonstrated in other gene therapy trials for LHON 
(26-29).  
Regarding potential mechanisms for the observed contralateral improvement, the most 
intriguing explanation would be the inter-eye transfer of the rAAV2/2-ND4 viral vector. In one 
rodent study, fluorogold nerve tracer dye injected intravitreally into rat eyes was detected in the 
optic nerves of the contralateral non-injected eyes, implying axonal or glial transfer through the 
anterior visual pathways (30). There is also evidence supporting the transneuronal spread of 
AAV, possibly through synaptic transfer mechanisms (31). Mitochondria have been shown to 
migrate long distances in axons to distribute energy and allow for distal neuronal activity (32). 
Mitochondria within RGC axons can also be engulfed into vesicles and exported to astrocytes 
that are found at a high density in the optic nerve head and then stored in endosomes (33,34). 
The dense network of interconnected astrocytic processes could, therefore, allow for the long-
distance cell-to-cell transfer of cytoplasmic elements via membrane junctions (35). Another 
hypothetic underlying mechanism for the contralateral improvement is brain plasticity with 
reorganization of the visual areas contributing to the visual improvement in the contralateral non-
injected eyes (36,37).  
To explore potential inter-eye transfer, we conducted an equivalent biodistribution study 
in healthy cynomolgus monkeys. Viral vector DNA was detected in quantifiable amounts in the 
anterior segment, retina and optic nerve of the non-injected eye three months following unilateral 
injection of rAAV2/2 ND4. Although the presence of viral vector DNA in the optic chiasm 
provides a possible clue to the diffusion pathway, our study was not designed to address the 
exact mechanisms underlying this transfer. The detection of viral vector DNA in the anterior 
segment of the non-injected eye is also interesting. Additional work is needed to clarify these 
important observations that have broader relevance to the design of gene therapy trials for optic 
neuropathies. 
The results of REVERSE raise a number of fundamental questions about the prospect of 
gene therapy for LHON and the best approach to correct the underlying pathogenic mtDNA 
mutation. The extent of visual recovery seen in patients treated with rAAV2/2-ND4 is more than 
what one would have expected based on the analysis of the published natural history data, which 
shows a much lower rate of recovery for this specific mutation (38). However, we did not have a 
prospective control group of untreated patients carrying the m.11778G>A mtDNA mutation 
assessed using the same comprehensive protocol with whom to make a direct comparison. If we 
consider that the improvement of vision does not reflect the natural history of LHON, but a true 
biological effect, the mechanisms that underpin the rescue of RGCs warrant further mechanistic 
investigations. Although speculative, it is also possible that the enhanced survival of RGCs could 
arise, at least partly, from the secondary effects of the intravitreal injection with the resulting 
inflammatory response increasing the expression of coactivators and transcription factors that 
upregulate mitochondrial biogenesis, which has been shown to be neuroprotective in the 
presence of a LHON mtDNA mutation (39,40,41). In turn, these mediators could find their way 
to the non-injected eye accounting for the unexpected bilateral improvement in visual function 
seen with a unilateral injection of rAAV2/2-ND4. Investigating this hypothesis would require a 
trial design that assigns one arm to receiving placebo intravitreal injection, which entails a 
number of safety and ethical considerations, in addition to patient acceptability. Furthermore, the 
intraocular inflammation seen with rAAV2/2-ND4 is generally mild and transient and it is 
unlikely to fully account for the sustained enhanced visual rescue. Another hypothesis, besides 
gene transfer, is the possible exchange of metabolic resources between the optic pathways (42). 
In conclusion, the REVERSE study showed bilateral improvement of visual function in 
LHON subjects treated with a unilateral intravitreal injection of rAAV2/2-ND4. The unexpected 
visual improvement observed in the contralateral non-injected eyes may reflect transfer of viral 
vector DNA from one eye to the other as demonstrated in our complementary NHP study. 
However, further investigations are needed to confirm these findings and their underlying 
mechanisms. This study, providing both clinical and preliminary experimental evidence for a 
bilateral effect of unilateral intravitreal injections targeting RGCs suggests that interocular 
diffusion of viral DNA vector could occur. These findings could have major implications for 
gene therapy clinical trial design and outcome measures. 
Materials and Methods 
Study Design 
REVERSE (NCT026527080) was a randomized, double-masked, sham-controlled, phase III 
clinical trial to evaluate the efficacy of a single intravitreal injection of rAAV2/2-ND4 in LHON 
subjects with the m.11778G>A mutation and vision loss occurring in both eyes in the prior 6 to 
12 months. A total of 37 subjects were enrolled in seven centers (France, Germany, Italy, United 
Kingdom and United States of America). The objective was to evaluate the efficacy of 
rAAV2/2-ND4 compared with a sham injection at Weeks 48 and 96, with the change from 
baseline in visual acuity expressed as the LogMAR as the primary efficacy endpoint. An interim 
analysis was planned at Week 72 to bring additional insights to Week 48 results. 
The right eye of each subject was randomly allocated to receive either treatment with 
rAAV2/2-ND4 via intravitreal (9E10 viral genomes in 90 μl per eye) or sham-treatment. The 
fellow (left) eye received the treatment not allocated to the right eye, in a 1:1 ratio. Treatment 
with prophylactic oral or topical steroids was not provided. Both eyes received standard 
antiseptic preparation with administered topical ocular anesthetic agent and underwent pupillary 
dilation. Before treatment, an intraocular pressure lowering agent was administered. The viral 
vector rAAV2/2-ND4 was administered in a single intravitreal injection. Following the same 
preparation steps preceding an intravitreal injection, a sham injection was performed on the 
sham-treated eye using the blunt end of a syringe and applying pressure to the eye at a typical 
injection site. Only the pharmacy team, the injecting physician and the medical team assisting in 
treatment were unmasked to treatment allocation. The unmasked study team performed the first 
assessment the day after treatment, whereas a separate medical team masked to treatment 
allocation performed all following ocular examinations.  
The protocol was reviewed and approved by independent ethic committees at all sites. 
The study was conducted in accordance with the principles and requirements of the International 
Conference on Harmonization Good Clinical Practice. An independent Data Safety Monitoring 
Board periodically reviewed study data to ensure the continued safe conduct of the trial and 
protection of subjects.  
To be enrolled, LHON subjects had to be 15 years or older, with duration of vision loss in 
both eyes between 6 and 12 months and visual acuity of at least counting fingers in each eye. 
Documented genotyping was required to confirm the presence of the m.11778G>A mutation in 
the MTND4 gene and the absence of other primary LHON-associated mutations (m.3460G>A in 
MTND1 or m.14484T>C in MTND6). The main exclusion criteria were known mutations in 
other genes involved in pathological retinal or optic nerve conditions, previous treatment with an 
ocular gene therapy product, glaucoma, optic neuropathy other than LHON, history of 
amblyopia, previous vitrectomy in either eye or ocular surgery of clinical relevance within 90 
days. Any prior use of idebenone was required to have ceased at least 7 days prior to enrollment. 
Outcome Measures 
Ophthalmic evaluations included assessment of BCVA using the ETDRS chart at 1 or 4 meters, 
assessment of contrast sensitivity using the Pelli-Robson chart, Humphrey Visual Field (HVF) 
30-2 testing, Farnsworth-Munsell 100-Hue Color Vision testing, slit-lamp biomicroscopy, 
Goldmann applanation tonometry, fundoscopy SD-OCT, and color fundus photography.  
When subjects could not read any letters on the ETDRS chart, they were asked to count 
the assessor’s fingers or to detect hand motion. An off-chart Snellen equivalent was derived 
using both the distance at which the assessment was made and the size of the assessor’s fingers, 
as described by Karanjia et al (43). The method was also adapted to hand motion visual acuity to 
provide conversion into a LogMAR value. Light perception and no light perception visual 
acuities were assigned a value of 4.0 and 4.5 LogMAR, respectively.  
Contrast sensitivity (CS) – the reciprocal of contrast threshold – was measured using the 
Pelli-Robson chart at 1 meter, performed according to test instructions and expressed as a 
logarithm (LogCS). Subjects who could not read any letter on the Pelli-Robson chart were 
assigned the worst possible score (0 LogCS). Intraocular inflammation was assessed and graded 
according to the Standardization of Uveitis Nomenclature (SUN) (44) and the National Institutes 
of Health Grading Scale for Vitreous Haze (45). 
Spectral domain-OCT was performed with the Spectralis OCT (Heidelberg Engineering). 
Parameters were measured for the optic nerve (Retinal Nerve Fiber Layer [RNFL], Ganglion 
Cell Layer [GCL], RNFL of the Papillo Macular Bundle [PMB]) and posterior pole per standard 
protocols included in the Spectralis software. At pre-specified visits, certified technicians 
performed one “Optic Nerve Head – Radial Scan and Concentric Circle Scan” (ONH-RC) and 
one “Posterior Pole N Scan” (PPoleN) for each eye, after maximal dilation. A reading center 
masked to treatment allocation - the Optic Nerve Research Center (ONRC) - performed quality 
control, analysis, and interpretation of all SD-OCT data.  
The standardized automated HVF 30-2, Central Threshold, SITA-FAST procedure was 
performed with the HVF Analyzer II. The reliability of the HVF test results were quality 
controlled by the ONRC reading center and the HVF test was repeated if considered unreliable 
by that center (defined as fixation losses ≥ 15%, false positive errors ≥ 20%, or false negative 
errors ≥ 33%).  
Quality of life was assessed at enrolment and Week 96 using the NEI VFQ-25 (22). The 
VFQ-25 consists of 25 vision-targeted questions representing 11 vision-related constructs, and a 
General-Health rating question. All items were scored so that a high score on a 0 to 100 scale 
represents better functioning. An overall Composite Score was calculated as the average of the 
vision-targeted subscale scores, excluding the General-Health rating question. For each subscale, 
change from baseline was calculated in terms of average score increase/decrease, and as the 
average of percent changes in scores. 
Statistical Analyses 
The primary endpoint for the REVERSE study was the change from baseline to Week 48 of 
LogMAR BCVA following treatment. A difference of -0.3 LogMAR (15 ETDRS letters 
equivalent) between the change from baseline in the rAAV2/2-ND4-treated eyes and the 
sham-treated eyes was considered clinically significant based on the U.S. Food and Drug 
Administration (FDA) recommendations. The sample size calculation was based on the primary 
endpoint and on the paired comparison of rAAV2/2-ND4-treated and sham-treated eye. The 
sample size calculation through paired comparison required assumptions due to the absence of 
published data on the within-subject correlation between right and left eyes and on the within- 
and between-subject variance of the LogMAR acuity. Based on available data (14), the sample 
size required to have a power of 85% was 36 subjects.  
The baseline value of functional endpoints (BCVA, CS, HVF 30-2) was defined as the 
last reported value prior to treatment administration, considering the subacute progression of 
visual signs. For OCT parameters, baseline was defined as the average value of screening and 
baseline visits assessments. We defined the “nadir” during the course of the study as the worst 
BCVA for each eye of each subject from baseline to Week 96 (including baseline and Week 96 
values). By definition, the change in BCVA from nadir for each eye results in no change or 
improvement. A statistical analysis plan was prepared after the study protocol was approved 
before the database lock. 
The efficacy analyses were run using the intent-to-treat population including all subjects 
who were randomized and received the actual study treatment (rAAV2/2-ND4). The safety 
analyses were run using the safety population including all subjects who received study 
treatment (rAAV2/2-ND4).  
The change of LogMAR BCVA from baseline to Week 96 in rAAV2/2-ND4-treated eyes 
was compared to that in sham-treated eyes (intra-subject comparison) using a mixed-effects 
analysis of covariance (ANCOVA) model with subject and eyes of the subject as random factors, 
treatment as a fixed effect, and baseline LogMAR BCVA as a covariate. The difference in the 
mean change from baseline between the two treatment groups and associated 95% confidence 
interval were reported. Statistical significance was assessed using an alpha of 0.05. 
In order to compare our results with previously published data on the natural history of 
LHON, two responder analyses were performed using different responder definitions. In the first 
responder analysis, a CRR at Week 96 was defined as either an eye that was on-chart (able to see 
letters on the chart) at baseline and that showed an improvement of at least 10 ETDRS letters, or 
an eye that was off-chart (not able to see letters on the chart) at baseline and that became able to 
read 5 ETDRS letters on-chart at 1 meter (6,19,20). A subject responder was defined as having 
this response in at least one eye at Week 96. In the second responder analysis, an eye responder 
at Week 96 was defined as an on-chart improvement of at least -0.3 LogMAR (3 ETDRS lines), 
or an improvement from off-chart to on-chart vision with a final BCVA of 1.4 LogMAR or 
better (able to read at least the first 3 ETDRS lines of the chart at 1 meter) (21). A subject 
responder was defined as having this response in at least one eye at Week 96. We opted for the 
first responder analysis, CRR, as this approach was considered by the European Medicines 
Agency (EMA) in its assessment of the efficacy of idebenone (Raxone, Santhera) in LHON (6). 
A group of experts have also endorsed the use of CRR as a valid outcome measure when 
assessing the effect of treatment with idebenone in LHON (1). 
Non-Human Primate Study 
Methods 
Four healthy male purpose-bred cynomolgus monkeys (Macaca fascicularis) were allocated to 
groups using a computerized stratification procedure so that the average body weight of each 
group was similar. At the beginning of the treatment period, the animals were at least 24 months 
old and with body weights between 3 and 5 kg. Formulations were administered by unilateral 
intravitreal injection in the right eye on Day 1 under a volume of 90 μL. Following injection, the 
animals were kept for an observation period of 3 months ± 2 days (with day 1 corresponding to 
the day of treatment). Group 1 included one control animal receiving unilateral intravitreal 
injection of vehicle, composed of formulation buffer (balanced sterile saline solution [BSSS 
buffer] supplemented with 0.001% Pluronic F68). Group 2 included 3 test animals receiving 
unilateral intravitreal injection of rAAV2/2-ND  (S222/DP0014/FC003 batch, Novasep), 
formulated in BSSS buffer supplemented with 0.001% Pluronic F68 to reach a dose of 4.3x1010 
viral genomes (vg) in 90 μL injected in the right eye. The 4.3x1010 vg dose was determined 
based on animal toxicology studies previously conducted and it corresponds to the human 
injected rAAV2/2-ND4 dose, proportional to the vitreous volume of the cynomolgus monkeys.  
At the end of the 3-month observation period, the animals were necropsied, and the 
following tissues were sampled from each animal (with right and left sides being collected and 
preserved separately): vitreous humor, aqueous humor, anterior segment of the eye (including 
cornea, iris, lens and choroid), lacrimal gland, retina, optic nerve, optic chiasm, lateral geniculate 
nucleus, optic tract and visual cortex. Analyses consisted of qPCR (DNA) targeting the ND4 
transgene of rAAV2/2-ND4. Special attention was given to sample collection to avoid cross-
contamination. Tissues and fluids were collected first for Group 1 control animals. Amongst the 
treated animals, tissues and fluids related to the non-treated eye were collected first. A clean set 
of disposable sterile instruments was used for each animal and for each tissue collected. The 
precise times of sacrifice of the animals and of snap freezing of the tissues were recorded.  
DNA from tissues was extracted using the Nucleospin Tissue kit (Macherey-Nagel). 
Tissue samples, except the anterior segment of the eye samples, were homogenized in 1 mL of 
T1 buffer. The anterior segment of the eye was entirely sampled and weighed. All the samples 
were homogenized into 2 mL of T1 buffer. For each tissue sample, 400 μL of the homogenized 
tissue were used for the extraction. The remaining homogenized tissue was kept at -80°C until 
further notice. Each tissue was weighed before the DNA extraction step. To the extent possible, 
tissue samples of minimum 20-30 mg (around 3 x 3 x 3 mm for small organs) and tissue sample 
of minimum 80 mg (around 5 x 5 x 5 mm for larger organs) were used. The volume of each fluid 
was measured before the DNA extraction step. Sentinel controls are samples composed by the 
first reagent that are usually added onto the biological material to monitor the potential cross-
contamination between samples during the extraction process. Sentinel controls were included 
within each DNA extraction batch. DNA concentration and purity were determined by UV 
spectrophotometry. DNA was then stored at -20°C until analysis. 
The extracted DNA was used as a template for qPCR amplification. The TaqMan qPCR 
protocol specifically targets the ND4 transgene of rAAV2/2-ND4. The qPCR protocol was 
validated in a previous dedicated study and the analytical parameters for sensitivity, specificity 
and accuracy were determined. Each qPCR contained 5 μL of DNA corresponding to 400 ng of 
DNA when feasible (or 400 ng of herring sperm for NTC sample, or 5 μL of ultrapure nuclease-
free water for no DNA sample or 5 μL of eluate from sentinel controls), and 20 μL of the qPCR 
master mix was composed of PCR Master Mix 2X (12.5 μL), forward-primer and reverse-primer 
(300 nM each), TaqManProbe (150 nM), and ultrapure nuclease-free water (qsp 20 μL). PCR 
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Fig 1. (A) Mean Change from Baseline in BCVA up to 96 Weeks Post-Administration of 
rAAV2/2-ND4 Gene Therapy.  Error bars: ±1 standard error. The Y-axis was inverted to 
represent BCVA improvement going upward. The asterisks indicate a statistically significant 
change from baseline (*p<0.05, **p<0.01, ***p<0.001). (B) Individual Changes in LogMAR 
BCVA from Baseline to Week 96 in REVERSE Subjects. CRR: clinically relevant response at 
Week 96. Subject with a CRR in at least one eye: defined as at least one eye that was on-chart at 
baseline and had an improvement of at least 10 ETDRS letters, or was off-chart at baseline and 
became on-chart with at least 5 ETDRS letters read. Data labels represent subject ID numbers. 
The X and Y-axes were inverted to represent BCVA improvement going right for sham-treated 
eyes and upward for rAAV2/2-ND4 eyes. The diagonal bisector indicates equal change in BCVA 
in both eyes of a subject. In the REVERSE study, 68% of the subjects experienced a CRR in at 
least one eye (points colored in green, red and blue), and 78% of the subjects experienced a 
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Table 1. Change of Best-Corrected Visual Acuity from Baseline to Week 96 
Best-Corrected Visual Acuity (LogMAR) rAAV2/2-ND4 Eyes Sham-Treated Eyes 
At Baseline 
n  37 37 
Mean (SD)  1.67 (0.50) 1.55 (0.42) 
Min, Max 0.80, 3.17 0.70, 2.81 
Change from 
Baseline 
n  37 37 
LS Mean (SE)  -0.308 (0.068) -0.259 (0.068) 
95% CI  -0.446, -0.170 -0.396, -0.121 





n  37 
LS Mean (95% CI) -0.049 (-0.144, 0.046) 
p-value  0.3019 
(1) A mixed-effects analysis of covariance (ANCOVA) model was used with change 
from baseline at as the response, and subject and eyes of the subject as random 
factors, treatment as a fixed effect, and the baseline LogMAR value as covariate. P-
value is used to assess the significance of the difference between All-rAAV2/2-ND4 
and All-Sham with respect to change from baseline. 
CI = confidence interval; LogMAR = logarithm of the minimal angle resolution; LS = 
least square; SD = standard deviation; SE = standard error 
  
Table 2. Change of Best-Corrected Visual Acuity from Nadir to Week 96 
 
 
Best-Corrected Visual Acuity rAAV2/2-ND4 Eyes Sham-Treated Eyes 
Change from Nadir 
n 37 37 
Mean LogMAR -0.570 -0.490 
Letters Equivalent +28.5 +24.5 
The mean improvement in BCVA from nadir to Week 96 was converted from LogMAR 
to “letters equivalent” by multiplying the LogMAR value by -50 (46). Nadir is defined as 
the worst BCVA recorded in any of the visits in REVERSE, including the baseline visit 
immediately prior to the injection. BCVA = best-corrected visual acuity; LogMAR = 




Table 3. rAAV2/2-ND DNA Detection and Quantification in Tissues from the Eye and the 
Central Nervous System 
 
3 Months 





















Lacrimal gland 1   1   2 1   1 2 (4.35 x 102) 
Anterior segment 
of the eye 1   1     3 (3.39 x 103)   3 (3.21 x 106) 
Aqueous humor 1   1   3    1 2 (1.65 x 103) 
Vitreous humor 1 1 3 3 (8.70 x 104) 
Retina 1   1    1 2 (5.99 x 103)  1 2 (2.70 x 106) 
Optic nerve 1   1     3 (1.00 x 104)  1 2 (1.45 x 103) 
Optic chiasm 1 1 3 1 2 (3.28 x 104) 
Optic tract 1 1 1 2 3 
Lateral 
geniculate 
nucleus 1   1   1 2   2 1 (2.84 x 102) 
Visual cortex 1 1 3 2 1 (2.05 x 103) 
*Quantity in copy/µg of DNA for tissue samples and copy/ µL for aqueous and vitreous humors. 
BLD: Below Limit of Detection (15.6 copies/μg of DNA); BLQ: Below Limit of Quantification 







Figure 2. Detection of rAAV2/2-ND4 DNA in Tissues from the Eye and the Central 
Nervous System 
The bar graph indicates the number of animals (out of 3) in which rAAV2/2-ND4 DNA was 
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Fig. S1. Mean Change from 
Administration of rAAV2/2-







Baseline in Contrast Sensitivity up to 96 Weeks Post
ND4 Gene Therapy 
 
              
 
-
Table S1. Baseline Characteristics of Subjects Enrolled in the REVERSE Study 
 All Subjects (N = 37) 
Age (Years) Mean (SD) 34.2 (15.2) 
 Min, Max 15, 67 
Gender   
Female n (%) 8 (21.6) 
Male n (%) 29 (78.4) 
Duration of Vision Loss (Days) 
rAAV2/2-ND4 eyes Mean (SD) 263.1 (53.9) 
 Min, Max 181, 362 
Sham-Treated eyes Mean (SD) 278.8 (64.5) 
 Min, Max 181, 364 
 
  
Table S2. Change from Baseline to Week 96 for Contrast Sensitivity, Humphrey Visual 
Field Perimetry and OCT Parameters 
 rAAV2/2-ND4 Eyes Sham-Treated Eyes 
Contrast Sensitivity (LogCS) 
At Baseline 
n  37 37 
Mean (SD)  0.25 (0.40) 0.35 (0.46) 
Min, Max 0.00, 1.50 0.00, 1.35 
Change from 
Baseline 
n  37 37 
LS Mean (SE)  0.22 (0.06) 0.12 (0.06) 





n  37 
LS Mean (95% CI) 0.10 (-0.02, 0.21) 
p-value  0.1036 
 
  
 rAAV2/2-ND4 Eyes Sham-Treated Eyes 
Mean Deviation (dB) HVF 
At Baseline 
n  37 37 
Mean (SD)  -25.99 (8.37) -24.94 (9.70) 
Min, Max -34.64, -1.80 -34.64, -3.20 
Change from 
Baseline 
n  37 37 
LS Mean (SE)  2.70 (0.90) 2.57 (0.90) 





n  37 
LS Mean (95% CI) 0.13 (-1.32, 1.59) 




 rAAV2/2-ND4 Eyes Sham-Treated Eyes 
RNFL Thickness - PMB (μm) 
At Baseline 
n  37 37 
Mean (SD)  23.1 (6.2) 23.6 (7.2) 
Change from 
Baseline 
n  35 36 
LS Mean (SE)  1.2 (1.3) 0.7 (1.3) 





n  35 
LS Mean (95% CI) 0.6 (-2.8, 3.9) 
p-value  0.7412 
RNFL Thickness - Temporal Quadrant (μm) 
At Baseline 
n  37 37 
Mean (SD)  27.5 (7.4) 28.9 (8.5) 
Change from 
Baseline 
n  35 36 
LS Mean (SE)  -1.8 (1.0) -2.0 (0.9) 





n  35 
LS Mean (95% CI) 0.2 (-2.2, 2.7) 
p-value  0.8465 
 
  
 rAAV2/2-ND4 Eyes Sham-Treated Eyes 
GCL Macular Volume (mm3) 
At Baseline 
n  37 37 
Mean (SD)  0.534 (0.063) 0.526 (0.069) 
Change from 
Baseline 
n  36 36 
LS Mean (SE)  -0.018 (0.012) -0.031 (0.012) 





n  36 
LS Mean (95% CI)  0.013 (-0.016, 0.042) 
p-value  0.3528 
 
(1) A mixed-effects analysis of covariance (ANCOVA) model was used with change from baseline at as the 
response, and subject and eyes of the subject as random factors, treatment as a fixed effect, and the 
baseline LogMAR value as covariate. P-value is used to assess the significance of the difference between 
All-rAAV2/2-ND4 and All-Sham with respect to change from baseline. 
(2) Subjects who could not read any letter on the Pelli-Robson chart were assigned the worst possible 
score (0 LogCS). 
CI = confidence interval; GCL = ganglion cell layer; HVF = Humphrey visual field; LS = least square; PMB = 
papillo-macular bundle; RNFL = retinal nerve fiber layer; SD = standard deviation; SE = standard error 
 
  
Table S3. Visual Responders at Week 96 
 Eye Responders Subject Responders 
 rAAV2/2-ND4 Sham  
Clinically relevant response (CRR) (1) 
Responder 23 (62%) 16 (43%) 25 (68%) 
Non-Responder 14 (38%) 21 (57%) 12 (32%) 
 p = 0.0348 (2)  
BCVA improvement by at least 3 ETDRS lines (3)  
Responder 13 (35%) 10 (27%) 15 (41%) 
Non-Responder 24 (65%) 27 (73%) 22 (59%) 
 p = 0.2568 (2)  
 
(1) CRR was defined per treatment group as either an eye which is on-chart at baseline with an 
improvement at Week 96 of at least 10 ETDRS letters, or an eye which is off-chart at 
baseline that became on-chart with at least 5 letters read at Week 96. A subject responder 
was defined as having a CRR in at least one eye at Week 96. 
(2) p-value from McNemar test compares the rates of eye responders between treatments. 
(3) Responder was defined as an on-chart improvement by at least -0.3 LogMAR (3 ETDRS lines), 
or an improvement from off-chart to on-chart vision with a final BCVA of 1.4 LogMAR or 
better (i.e. at least the first 3 ETDRS lines of the chart were read at 1 meter). A subject 
responder was defined as having this response in at least one eye at Week 96. 
CRR: clinically relevant response. 
  
Table S4. Change in Vision-Related Quality of Life at Week 96 
VFQ-25 Subscales (1) Baseline Score Change from Baseline 
 Mean (SD) Mean (SD) Mean %(2) 
Dependency 31.8 (24.7) +18.5 (28.9) 130.2% 
Mental Health 32.1 (24.6) +16.1 (18.9) 108.2% 
Role Difficulties 34.5 (28.3) +15.9 (28.4) 78.9% 
Near Activities 23.7 (14.8) +13.3 (22.0) 78.1% 
Peripheral Vision 59.5 (27.2) +10.8 (26.0) 41.0% 
Distance Activities 35.5 (18.7) +10.7 (18.6) 47.4% 
Color Vision 68.1 (29.6) +6.9 (21.2) 21.6% 
General Vision 30.8 (13.0) +6.5 (17.0) 32.40% 
Social Functioning 49.0 (23.5) +4.7 (24.4) 32.80% 
Ocular Pain 84.8 (18.4) -1.0 (20.7) 1.60% 
Composite Score (3) 42.1 (15.5) +9.5 (12.7) +28.8% 
(1) Subscales not reported in this table: General Health (missing values), Driving (not applicable 
to LHON). 
(2) The mean percent change from baseline was calculated from individual percent changes 
from baseline.  
(3) The Composite Score is the average of vision-targeted sub-scale scores, excluding the 
General Health rating question. 
 
 
